RESUMO
Despite years of drug development, electroconvulsive therapy (ECT) remains the most effective treatment for severe depression. The exact therapeutic mechanism of action of ECT is still unresolved and therefore we tested the hypothesis that the beneficial effect of ECT could in part be the result of increased noradrenergic neurotransmission leading to a decrease in α2-adrenoceptor binding. We have previously shown that both the Flinders sensitive line (FSL) and Flinders resistant line (FRL) rats had altered α2-adrenoceptor binding compared to control Sprague-Dawley (SD) rats. In this study, we treated female FSL, FRL and SD rats with electroconvulsive shock (ECS), an animal model of ECT, or sham stimulation for 10 days before brains were removed and cut into 20µm thick sections. Densities of α2-adrenoceptors were measured by quantitative autoradiography in the hippocampus, thalamic nucleus, hypothalamus, amygdala, frontal cortex, insular cortex, and perirhinal cortex using the α2-adrenoceptor antagonist, [(3)H]RX 821002. ECS decreased the binding of α2-adrenoceptors in cortical regions in the FSL and cortical and amygdaloid regions in the control FRL rats compared to their respective sham treated group. The normal SD controls showed no significant response to ECS treatment. Our data suggest that the therapeutic effect of ECS may be mediated through a decrease of α2-adrenoceptors, probably due to a sustained increase in noradrenaline release. These data confirm the importance of the noradrenergic system and the α2-adrenoceptor in depression and in the mechanism of antidepressant treatments.
Assuntos
Encéfalo/metabolismo , Depressão/metabolismo , Depressão/terapia , Eletrochoque/métodos , Receptores Adrenérgicos alfa 2/metabolismo , Antagonistas Adrenérgicos alfa/farmacocinética , Análise de Variância , Animais , Autorradiografia , Biofísica , Encéfalo/efeitos dos fármacos , Depressão/genética , Modelos Animais de Doenças , Feminino , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Ligação Proteica/efeitos dos fármacos , Ligação Proteica/efeitos da radiação , Ratos , Ratos Sprague-Dawley , Trítio/farmacocinéticaRESUMO
This study investigated the effects of intravenous (IV) administration of tetrathiomolybdate (TTM), and α(2)-adrenergic agonist clonidine (CLO) and α(2)-antagonist idazoxan (IDA), alone or in combination with TTM, on sheep fed low (LCu) and high (HCu) copper diets. Effects on bile flow, biliary Cu concentration and excretion, plasma Cu concentration, and lysosomal enzyme ß-glucuronidase (ß-GLU) activity in bile and plasma were determined. Tetrathiomolybdate alone or with CLO or IDA significantly enhanced biliary Cu excretion most likely by removing Cu from hepatocyte lysosomes as evidenced by a significant increase in ß-GLU enzyme activity in bile. A significant increase in plasma ß-GLU concentration occurred only in sheep treated with CLO in combination with TTM. Because of the lytic nature of the lysosomal enzymes, caution is advocated in use of drugs, especially α(2)-adrenergic agonists, to further enhance TTM-induced biliary Cu excretion in the treatment of chronic Cu poisoning in sheep.
Assuntos
Clonidina/farmacologia , Cobre/metabolismo , Idazoxano/farmacologia , Lisossomos/enzimologia , Molibdênio/farmacologia , Ovinos/metabolismo , Agonistas de Receptores Adrenérgicos alfa 2/farmacocinética , Agonistas de Receptores Adrenérgicos alfa 2/farmacologia , Antagonistas de Receptores Adrenérgicos alfa 2/farmacocinética , Antagonistas de Receptores Adrenérgicos alfa 2/farmacologia , Animais , Bile/química , Bile/enzimologia , Bile/metabolismo , Clonidina/farmacocinética , Cobre/análise , Feminino , Regulação Enzimológica da Expressão Gênica , Glucuronidase/metabolismo , Idazoxano/farmacocinética , Lisossomos/metabolismo , Molibdênio/farmacocinéticaRESUMO
I2 imidazoline receptors (I2Rs) are associated with depression, Alzheimer's disease, and Huntington's disease. However, in vivo imaging of I2Rs in the monkey brain has not been reported until now. We performed in vitro and in vivo imaging of (I2Rs) in the monkey brain using ¹¹C-labeled 2-(3-fluoro-4-tolyl)-4,5-dihydro-1H-imidazole ([¹¹C]FTIMD) which has high and selective affinity of I2Rs. In an auto-radiography (ARG) study, the distribution pattern of [¹¹C]FTIMD in the monkey brain was similar to that of [³H]idazoxan binging to I2Rs in the human brain, which was previously described. The specific binding of [¹¹C]FTIMD accounted for >97% of total binding in brain regions existing I2 Rs. In positron emission tomography (PET) studies, the radioactivity was accumulated in brain regions existing I2Rs ligand BU224, the accumulated radioactivity was decreased to approximately 66%-75% of the baseline measurement at 15-45 min after injection of [¹¹C]FTIMD. These results suggest that [¹¹C]FTIMD shows the specific-binging to I2Rs in the monkey brain as depicted by PET and ARG. We performed the first in vivo imaging of I2Rs using [¹¹C]FTIMD in the monkey brain.
Assuntos
Mapeamento Encefálico , Encéfalo/metabolismo , Receptores de Imidazolinas/metabolismo , Antagonistas de Receptores Adrenérgicos alfa 2/farmacocinética , Animais , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Radioisótopos de Carbono/farmacocinética , Idazoxano/farmacocinética , Imidazóis/farmacocinética , Receptores de Imidazolinas/antagonistas & inibidores , Técnicas In Vitro , Macaca mulatta , Masculino , Tomografia por Emissão de Pósitrons/métodos , Ligação Proteica/efeitos dos fármacos , Fatores de TempoRESUMO
L-DOPA-induced dyskinesia is characterised by debilitating involuntary movement, which limits quality of life in patients suffering from Parkinson's disease. Here, we investigate effects of the a2 adrenoceptor antagonist idazoxan on L-DOPA-induced dyskinesia as well as on alterations of extracellular L-DOPA and dopamine (DA) levels in the striatum in dyskinetic rats. Male Wistar rats were unilaterally lesioned with 6-hydroxydopamine and subsequently treated with L-DOPA/benserazide to induce stable dyskinetic movements.Administration of idazoxan [(9 mg/kg, intraperitoneal (i.p.)]significantly alleviated L-DOPA-induced dyskinesia, whereas idazoxan (3 mg/kg, i.p.) did not affect dyskinetic behaviour.Bilateral in vivo microdialysis revealed that idazoxan 9 mg/kg reduces extracellular peak L-DOPA levels in the lesioned and intact striatum as well as DA levels in the lesioned striatum. In parallel, the exposure to idazoxan in the striatum was monitored.Furthermore, no idazoxan and L-DOPA drug-drug interaction was found in plasma, brain tissue and CSF. In conclusion, the decrease of L-DOPA-derived extracellular DA levels in the lesioned striatum significantly contributes to the anti-dyskinetic effect of idazoxan.
Assuntos
Antagonistas Adrenérgicos alfa/uso terapêutico , Corpo Estriado/metabolismo , Dopamina/metabolismo , Discinesia Induzida por Medicamentos/tratamento farmacológico , Idazoxano/uso terapêutico , Adrenérgicos/toxicidade , Antagonistas Adrenérgicos alfa/farmacocinética , Análise de Variância , Animais , Antiparkinsonianos/efeitos adversos , Antiparkinsonianos/farmacocinética , Cromatografia Líquida de Alta Pressão/métodos , Corpo Estriado/efeitos dos fármacos , Modelos Animais de Doenças , Discinesia Induzida por Medicamentos/etiologia , Idazoxano/farmacocinética , Levodopa/efeitos adversos , Levodopa/farmacocinética , Masculino , Microdiálise/métodos , Síndromes Neurotóxicas/complicações , Síndromes Neurotóxicas/tratamento farmacológico , Síndromes Neurotóxicas/etiologia , Oxidopamina/toxicidade , Ratos , Ratos Wistar , Espectrometria de Massas em Tandem/métodosRESUMO
In Alzheimer's disease (AD) there is a significant loss of locus coeruleus (LC) noradrenergic neurons. However, recent work has shown the surviving noradrenergic neurons to display many compensatory changes, including axonal sprouting to the hippocampus. The prefrontal cortex (PFC) is a forebrain region that is affected in dementia, and receives innervation from the LC noradrenergic neurons. Reduced PFC function can reduce cognition and disrupt behavior. Because the PFC is an important area in AD, we determined if noradrenergic innervation from the LC noradrenergic neurons is maintained and if adrenoreceptors are altered postsynaptically. Presynaptic PFC alpha2-adrenoreceptor (AR) binding site density, as determined by 3H-RX821002, suggests that axons from surviving noradrenergic neurons in the LC are sprouting to the PFC of subjects with dementia. Changes in postsynaptic alpha1-AR in the PFC of subjects with dementia indicate normal to elevated levels of binding sites. Expression of alpha1-AR subtypes (alpha1A- and alpha1D-AR) and alpha2C-AR subtype mRNA in the PFC of subjects with dementia is similar to what was observed in the hippocampus with one exception, the expression of alpha1A-AR mRNA. The expression of the alpha1A-AR mRNA subtype is significantly reduced in specific layers of the PFC in subjects with dementia. The loss of alpha1A-, alpha1D- and alpha2C-AR mRNA subtype expression in the PFC may be attributed to neuronal loss observed in dementia. These changes in postsynaptic AR would suggest a reduced function of the PFC. Consequence of this reduced function of the PFC in dementia is still unknown but it may affect memory and behavior.
Assuntos
Demência/patologia , Regulação da Expressão Gênica/fisiologia , Córtex Pré-Frontal/metabolismo , Receptores Adrenérgicos/metabolismo , Antagonistas Adrenérgicos alfa/farmacocinética , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Masculino , Pessoa de Meia-Idade , Mudanças Depois da Morte , Prazosina/farmacocinética , Córtex Pré-Frontal/patologia , RNA Mensageiro/metabolismo , Receptores Adrenérgicos/classificação , Receptores Adrenérgicos/genéticaRESUMO
Knowledge about the noradrenergic system in birds is very scarce even though their biological diversity and complex social behavior make them an excellent model for studying neuronal functions and developmental biology. While the role of norepinephrine has been described in depth in a large number of central and peripheral functions in mammals, reports for avian species are limited. The radioligand [(3)H]RX 821002 ([(3)H]1,4-[6,7(n)3H]-benzodioxan-2-methoxy-2-yl)-2-imidazol) has been used to map and characterize alpha(2)-adrenoceptors through the chicken brain using in vitro autoradiography and membrane homogenates binding assays. [(3)H]RX 821002 showed a saturable and high affinity binding to a site compatible with alpha(2)-adrenoceptor, and to a serotonergic component. The autoradiographic assays displayed a similar alpha(2)-adrenoceptor distribution than those previously reported in birds using other radioligands such as [(3)H]UK 14304 ([(3)H]5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine) or [(3)H]clonidine. [(3)H]RX 821002 binding pharmacological characterization was carried out in different chicken brain regions using membrane homogenates for competition assays with different alpha(2)-adrenoceptor agonists and antagonists drugs (oxymetazoline, BRL 44408 [2-(2H-(1-methyl-1,3-dihydroisoindole)methyl)-4,5-dihydroimidazole] ARC 239 [2-(2-4-(O-methoxyphenyl)-piperazin-1-yl)-ethyl-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione], prazosin, UK 14304 and RX 821002). The results showed alpha(2A) as the predominant alpha(2)-adrenoceptor subtype in the chicken brain while alpha(2B)- and/or alpha(2C)-adrenoceptor subtypes were detected only in the telencephalon. RX 821002, serotonin (5-HT) and 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] competition assays, and competition binding assays performed in the presence of serotonin demonstrated that [(3)H]RX 821002 binds with higher affinity to a serotonergic component, probably 5-HT(1A) receptors, than to the alpha(2)-adrenoceptors. Similar pharmacological properties for the alpha(2)-adrenoceptor component were observed both in rat and chicken brain. The results demonstrate that the different alpha(2)-adrenoceptor subtypes are present in chicken brain and suggest that these receptors are highly conserved through evolution.
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos alfa/farmacocinética , Encéfalo/efeitos dos fármacos , Idazoxano/análogos & derivados , Agonistas alfa-Adrenérgicos/farmacologia , Animais , Ligação Competitiva/efeitos dos fármacos , Encéfalo/anatomia & histologia , Galinhas , Relação Dose-Resposta a Droga , Interações Medicamentosas , Idazoxano/farmacocinética , Idazoxano/farmacologia , Técnicas In Vitro , Masculino , Oximetazolina/farmacologia , Ensaio Radioligante/métodos , Ratos , Ratos Sprague-Dawley , Serotonina/farmacologia , Trítio/farmacocinéticaRESUMO
The present study investigated, by use of fos immunohistochemistry, whether the functional activity of alpha(1)-adrenoceptors is elevated during heightened behavioral activity in brain regions shown earlier to contain motoric alpha(1)-receptors. In confirmation, marked c-fos responses that were blocked by an alpha(1)-antagonist (prazosin) were found in four of these brain regions (secondary motor, cingulate, piriform cortices, and nucleus accumbens) of animals exposed to a mildly novel environment (clean cage), which elicits a high degree of sustained exploratory activity. Experimental restriction of exploratory activity in the novel cage by a small enclosure did not reduce the fos responses in these areas, and in fact, enhanced gene expression when carried out in home-caged animals suggesting that the fos response may be more closely associated with the motivation to be active rather than activity itself. Experiments with locally administered alpha(1)-agonists and antagonists in the cortex by reverse dialysis showed that the above mentioned alpha(1)-dependent-fos responses were the result of activation of local alpha(1)-receptors in these brain regions. Unlike the aforementioned brain regions, the fos response of the locus coeruleus was not blocked by prazosin, and this nucleus also showed a marked fos increase to prazosin itself possibly as a compensatory response to the blockade of forebrain alpha(1)-receptors.
Assuntos
Sistema Nervoso Central/metabolismo , Comportamento Exploratório/fisiologia , Proteínas Oncogênicas v-fos/metabolismo , Receptores Adrenérgicos alfa 1/fisiologia , Antagonistas Adrenérgicos alfa/farmacocinética , Antagonistas Adrenérgicos alfa/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Sistema Nervoso Central/anatomia & histologia , Sistema Nervoso Central/efeitos dos fármacos , Diálise/métodos , Comportamento Exploratório/efeitos dos fármacos , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Imuno-Histoquímica/métodos , Masculino , Fenilefrina/metabolismo , Prazosina/análogos & derivados , Prazosina/metabolismo , Prazosina/farmacologia , Ligação Proteica/efeitos dos fármacos , Ratos , Ratos WistarRESUMO
Opposite age-dependent changes in alpha2-adrenoceptor and imidazoline I2 receptor (I2-IRs) density have been related to brain gliosis development with aging. To check this hypothesis we applied in rats a model of reactive gliosis induced by heat. The specific binding of [3H]idazoxan (0.5-20 nM) in the presence of (-)adrenaline (5 x 10(-6) M) to membranes from rat brain cortex showed that the density of I(2)-IRs was significantly higher in membranes of injured cortex (Bmax=60+/-6 fmol/mg protein; n=9) than in control (Bmax=38+/-3 fmol/mg protein; n=9; p=0.0053). Conversely, the density of alpha2-adrenoceptors, measured by [3H]clonidine (0.25-16 nM), in the injured cortex (Bmax=75+/-4 fmol/mg protein; n=9) was significantly lower than in sham membranes (Bmax=103+/-7 fmol/mg protein; n=9; p=0.0035). No significant differences in receptor's affinity were observed between both groups. These results support the hypothesis that gliosis induces opposite changes in alpha2-adrenoceptor and I2-IR density.
Assuntos
Gliose/metabolismo , Córtex Pré-Frontal/metabolismo , Receptores Adrenérgicos alfa 2/metabolismo , Receptores de Droga/metabolismo , Actinas/metabolismo , Agonistas alfa-Adrenérgicos/farmacocinética , Antagonistas Adrenérgicos alfa/farmacocinética , Animais , Western Blotting , Membrana Celular/metabolismo , Clonidina/farmacocinética , Epinefrina/farmacocinética , Proteína Glial Fibrilar Ácida/metabolismo , Gliose/patologia , Temperatura Alta/efeitos adversos , Idazoxano/farmacocinética , Receptores de Imidazolinas , Masculino , Córtex Pré-Frontal/patologia , Ratos , Ratos Sprague-DawleyRESUMO
Noradrenaline plays an important role in many normal brain functions, e.g., attention, memory, and emotion. Dysfunction in the noradrenergic system is thought to lead to a number of abnormal brain conditions. The lack of suitable in vivo tracers to monitor noradrenaline release, levels, and regulation has hampered our fully understanding the roles that it plays in the brain. Presented here are data showing that the in vivo binding of the alpha2-adrenoceptor antagonist [3H]RX 821002 is sensitive to endogenous noradrenaline. Elevation of extracellular noradrenaline, using three different pharmacological challenges in rat, led to a reduction in the binding potential (BP) of [3H]RX 821002 when compared with vehicle controls. The challenges used were i.p. administration of D-amphetamine, the imidazoline2 binding site-selective ligand BU224, and L-deprenyl. Of the cortical regions measured, the reduction in BP reached significance in the anterior cingulate cortex for all of these pharmacological challenges. These initial observations in rat indicate that labelling of the alpha2-adrenoceptors with RX 821002 can be used to estimate changes in extracellular noradrenaline concentration in the cortex. This has the potential to enable the investigation of the role that noradrenaline plays both in the normal and abnormal brain and, if the ligand can be radiolabelled with a suitable positron-emitting isotope at high specific radioactivity, it could be an invaluable PET tracer.
Assuntos
Antagonistas Adrenérgicos alfa/farmacocinética , Encéfalo/metabolismo , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Norepinefrina/metabolismo , Inibidores da Captação Adrenérgica/farmacologia , Antagonistas Adrenérgicos alfa/química , Animais , Ligação Competitiva/efeitos dos fármacos , Encéfalo/anatomia & histologia , Encéfalo/efeitos dos fármacos , Dextroanfetamina/farmacologia , Idazoxano/química , Imidazóis/farmacologia , Masculino , Microdiálise/métodos , Inibidores da Monoaminoxidase/farmacologia , Ensaio Radioligante/métodos , Ratos , Ratos Wistar , Selegilina/farmacologia , Fatores de Tempo , Distribuição Tecidual , Trítio/farmacocinéticaRESUMO
Neonatal treatments can disrupt prepulse inhibition (PPI) of startle response later in life. Alpha2A-adrenergic receptors (alpha2A-ARs) regulate the release of brain neurotransmitters that may influence PPI. The authors examined the effects of short-term reduction in the neonatal brainstem alpha2A-ARs on subsequent development of this receptor system and acoustic startle reflex in rats. Administration of antisense oligodeoxynucleotide complementary to the alpha2A-ARs on Days 2-4 of life reduced receptor expression in the brainstem by Day 5. The treatment increased alpha2-AR numbers in the cortex, hippocampus, and amygdala at 40 days of age, and in cortex and hypothalamus at 90 days of age. Transient increases in hippocampal and amygdalar alpha2-ARs were accompanied by attenuation of acoustic startle response and impairment of PPI.
Assuntos
Tronco Encefálico/metabolismo , Idazoxano/análogos & derivados , Inibição Psicológica , Receptores Adrenérgicos alfa 2/metabolismo , Reflexo Acústico/fisiologia , Reflexo de Sobressalto/fisiologia , Antagonistas Adrenérgicos alfa/farmacocinética , Fatores Etários , Análise de Variância , Animais , Animais Recém-Nascidos , Comportamento Animal , Encéfalo/anatomia & histologia , Encéfalo/efeitos dos fármacos , Encéfalo/fisiologia , Tronco Encefálico/efeitos dos fármacos , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Idazoxano/farmacocinética , Oligonucleotídeos Antissenso/farmacologia , Ligação Proteica/efeitos dos fármacos , RNA Mensageiro/biossíntese , Ensaio Radioligante/métodos , Distribuição Aleatória , Ratos , Ratos Wistar , Receptores Adrenérgicos alfa 2/genética , Reflexo Acústico/efeitos dos fármacos , Reflexo de Sobressalto/efeitos dos fármacos , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Trítio/farmacocinéticaRESUMO
Brain alpha2-adrenergic receptors (alpha2-ARs) have been implicated in the regulation of anxiety, which is associated with stress. Environmental treatments during neonatal development could modulate the level of brain alpha2-AR expression and alter anxiety in adults, suggesting possible involvement of these receptors in early-life programming of anxiety state. The present study was undertaken to determine whether the reduction of the expression of A subtype of these receptors most abundant in the neonatal brain affects anxiety-related behavior in adulthood. We attenuated the expression of alpha2A-ARs during neonatal life by two different sequence specific approaches, antisense technology and RNA interference. Treatment of rats with the antisense oligodeoxynucleotide or short interfering RNA (siRNA) against alpha2A-ARs on the days 2-4 of their life, produced a marked acute decrease in the levels of both alpha2A-AR mRNA and [3H]RX821002 binding sites in the brainstem into which drugs were injected. The decrease of alpha2A-AR expression in the neonatal brainstem influenced the development of this receptor system in the brain regions as evidenced by the increased number of [3H]RX821002 binding sites in the hypothalamus of adult animals with both neonatal alpha2A-AR knockdown treatments; also in the frontal cortex of antisense-treated, and in the hippocampus of siRNA-treated adult rats. These adult animals also demonstrated a decreased anxiety in the elevated plus-maze as evidenced by an increased number of the open arm entries, greater proportion of time spent in the open arms, and more than a two-fold increase in the number of exploratory head dips. The results provide the first evidence that the reduction in the brain expression of a gene encoding for alpha2A-AR during neonatal life led to the long-term neurochemical and behavioral alterations. The data suggests that alterations in the expression of the receptor-specific gene during critical periods of brain development may be involved in early-life programming of anxiety-related behavior.
Assuntos
Ansiedade/tratamento farmacológico , Tronco Encefálico/efeitos dos fármacos , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Idazoxano/análogos & derivados , Oligodesoxirribonucleotídeos Antissenso/administração & dosagem , RNA Interferente Pequeno/administração & dosagem , Receptores Adrenérgicos alfa 2/metabolismo , Antagonistas Adrenérgicos alfa/farmacocinética , Análise de Variância , Animais , Animais Geneticamente Modificados , Animais Recém-Nascidos , Comportamento Animal , Southern Blotting/métodos , Tronco Encefálico/crescimento & desenvolvimento , Idazoxano/farmacocinética , Aprendizagem em Labirinto/efeitos dos fármacos , Norepinefrina/metabolismo , Ligação Proteica/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ensaio Radioligante , Ratos , Ratos Wistar , Receptores Adrenérgicos alfa 2/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Trítio/farmacocinéticaRESUMO
In recent years, it has been postulated that tramadol, used mainly for the treatment of moderate to severe pain, might display a potential as an antidepressant drug. The present study investigated the effects of acute and repeated tramadol administration on the binding of [3H]RX 821002, a selective alpha2-adrenergic receptor ligand, in the rat brain. Male Wistar rats were used. Tramadol (20 mg/kg, i.p.) administered acutely (single dose), at 24 h after dosing, induced a significant decrease in the alpha2-adrenergic receptors in all brain regions studied. The most pronounced effects were observed in all subregions of the olfactory system, nucleus accumbens and septum, thalamus, hypothalamus, amygdala, and cerebral cortex. Repeated treatment with tramadol (20 mg/kg, i.p., once daily for 21 days) also induced statistically significant downregulation of [3H]RX 821002 binding sites in the rat brain. However, the effect--although statistically significant--was less pronounced than in the group treated acutely with the drug. Since drugs such as mianserin and mirtazapine are potent antagonists of central alpha2-adrenergic receptors and are effective antidepressants, it is tempting to suggest that, in addition to other alterations induced by tramadol, downregulation of these receptors may represent a potential antidepressant efficacy. On the other hand, one should be careful to avoid the treatment of chronic pain with tramadol in patients already receiving antidepressant drugs. Tramadol-induced downregulation of alpha2-adrenergic receptors--when combined with ongoing antidepressant therapy with drugs, which themselves inhibit serotonin reuptake or are antagonists of alpha2-adrenergic receptors--might cause threatening complications.
Assuntos
Encéfalo/efeitos dos fármacos , Idazoxano/análogos & derivados , Entorpecentes/farmacologia , Receptores Adrenérgicos alfa 2/metabolismo , Tramadol/farmacologia , Antagonistas Adrenérgicos alfa/farmacocinética , Análise de Variância , Animais , Autorradiografia/métodos , Encéfalo/anatomia & histologia , Encéfalo/metabolismo , Esquema de Medicação , Idazoxano/farmacocinética , Masculino , Entorpecentes/administração & dosagem , Ligação Proteica/efeitos dos fármacos , Ratos , Ratos Wistar , Tramadol/administração & dosagem , Trítio/farmacocinéticaRESUMO
The imidazoline-type compound, MPV-1743, has been found to activate nonshivering thermogenesis (NST) in brown adipose tissue (BAT) of the genetically obese Zucker rats. The regulation of NST in BAT is linked to the catecholamine metabolism, and the imidazoline I2-binding sites have been found on the monoamine oxidase, a catecholamine metabolising enzyme. In this study, the I2-binding sites of hamster BAT have been characterised using a receptor binding assay with 3H-idazoxan as a radioligand, and the interaction of MPV-1743 with these I2-binding sites has been studied using the enantiomers of MPV 1743, that is, MPV 2088 and MPV 2089. Cirazoline was used to determine the specific binding of 3H-idazoxan to the imidazoline I2-binding sites. Rauwolscine was added in the 3H-idazoxan binding assay in order to inhibit any binding to potential alpha2-adrenergic sites. In the presence of rauwolscine mask 3H-Idazoxan labelled a population of non-adrenergic binding sites expressing the properties of the imidazoline I2b-receptor subtype similar to that found in the rat liver (cirazoline >> guanabenz = amiloride >> clonidine). The binding of 3H-idazoxan to the I2b-binding sites could be displaced by the imidazole compounds with the following affinities: detomidine (KiHigh 9.2 nM; KiLow 3200 nM), MPV-2088 (KiHigh 19 nM; IKiLow 760 nM) and MPV-2089 (KiHigh 190 nM; KiLow 1300 nM), atipamezole (3500 nM) and dexmedetomidine (Ki 8400 nM). These results have shown that the hamster BAT contains the imidazoline I2b-binding sites with heterogeneous binding properties for some test compounds. In addition, the enantiomers of MPV 1743, that is, MPV 2088 and MPV 2089, had high affinity to these BAT imidazoline I2b-binding sites. Therefore, it is suggested that the regulation of NST in the hamster BAT may be an attractive model to study the role of imidazoline I2b-binding sites.
Assuntos
Tecido Adiposo Marrom/química , Tecido Adiposo Marrom/metabolismo , Idazoxano/farmacocinética , Receptores de Droga/química , Receptores de Droga/metabolismo , Amilorida/química , Amilorida/farmacocinética , Animais , Sítios de Ligação , Ligação Competitiva , Linhagem Celular Tumoral , Clonidina/química , Clonidina/farmacocinética , Técnicas de Cultura , Relação Dose-Resposta a Droga , Guanabenzo/química , Guanabenzo/farmacocinética , Humanos , Idazoxano/química , Imidazóis/química , Imidazóis/farmacocinética , Receptores de Imidazolinas , Fígado/química , Fígado/metabolismo , Neoplasias Mamárias Animais , Camundongos , Ligação Proteica , Ratos , Especificidade da Espécie , Ioimbina/química , Ioimbina/farmacocinéticaRESUMO
One of the major differences between the atypical antipsychotic drugs clozapine and olanzapine is that clozapine has a two-fold higher affinity for the alpha(2)-adrenoreceptors. As clozapine can have therapeutic benefits in individuals that do not respond to other antipsychotic drugs, this raises the possibility that changes in the alpha(2)-adrenoreceptors could be a marker for a predisposition to treatment resistance. A methodology has been optimised to measure the binding of [3H]RX 821002 to alpha(2)-adrenoreceptors in human postmortem CNS and has shown that these receptors are not altered in Brodmann's area 9 from subjects with schizophrenia. These data add to those of one other study that showed the alpha(2)-adrenoreceptors were not altered in Brodmann's area 10 and the hippocampus from subjects with schizophrenia, and do not support the hypothesis that changes in alpha(2)-adrenoreceptors are a marker for treatment resistance in schizophrenia.
Assuntos
Antagonistas Adrenérgicos alfa/farmacocinética , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Córtex Pré-Frontal/metabolismo , Córtex Pré-Frontal/patologia , Esquizofrenia/metabolismo , Esquizofrenia/patologia , Antagonistas de Receptores Adrenérgicos alfa 2 , Adulto , Idoso , Benzodiazepinas/uso terapêutico , Sítios de Ligação , Clozapina/uso terapêutico , Feminino , Hipocampo/metabolismo , Hipocampo/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Mudanças Depois da Morte , Esquizofrenia/tratamento farmacológico , Antagonistas da Serotonina/uso terapêuticoRESUMO
When patients do not respond to an initial antidepressant, one clinical approach is to switch to an agent in a different pharmacological class. However, few studies have examined the neurochemical consequences of this practice. To study this, we examined changes in binding sites in rat brain for norepinephrine (NET) and serotonin transporters (SERT), alpha1, alpha2, and beta1 adrenergic receptors after chronic administration of paroxetine (PRX), reboxetine (RBX), or PRX followed by RBX. We also examined the effects of these treatments on mRNA expression for tyrosine hydroxylase (TH). RBX treatment for 3 weeks reduced NET binding significantly, by approximately 40% in terminal field areas, and 6 weeks of RBX reduced it even more, by approximately 60%. RBX treatment for 3 and 6 weeks reduced beta1 adrenergic receptor-binding sites equally, by 50-60%. At no time did RBX treatment reduce SERT-binding sites. PRX treatment had no effect on beta1 adrenergic or NET-binding sites, but reduced SERT-binding sites by 75-80%. Neither treatment altered mRNA for TH, alpha1, or alpha2 adrenergic receptor-binding sites. When 3 weeks of RBX treatment followed 3 weeks of PRX treatment, NET-binding sites were reduced to the same extent as measured after 6 weeks of RBX treatment alone, indicating that PRX pretreatment may have 'primed' the subsequent regulatory effect of RBX on the NET. Thus, pretreatment of rats with PRX actually enhanced at least one regulatory effect of RBX treatment on the noradrenergic system, and did not interfere with any other pharmacological effect caused by RBX treatment.
Assuntos
Inibidores da Captação Adrenérgica/farmacologia , Encéfalo/efeitos dos fármacos , Proteínas de Transporte/metabolismo , Glicoproteínas de Membrana/metabolismo , Proteínas de Membrana Transportadoras , Morfolinas/farmacologia , Proteínas do Tecido Nervoso , Paroxetina/farmacologia , Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Simportadores/metabolismo , Inibidores da Captação Adrenérgica/sangue , Antagonistas Adrenérgicos alfa/farmacocinética , Animais , Autorradiografia , Sítios de Ligação , Encéfalo/anatomia & histologia , Encéfalo/metabolismo , Mapeamento Encefálico , Cromatografia Líquida de Alta Pressão , Esquema de Medicação/veterinária , Interações Medicamentosas , Idazoxano/farmacocinética , Hibridização In Situ , Masculino , Morfolinas/sangue , Proteínas da Membrana Plasmática de Transporte de Norepinefrina , Ratos , Ratos Sprague-Dawley , Reboxetina , Receptores Adrenérgicos/classificação , Receptores Adrenérgicos/metabolismo , Proteínas da Membrana Plasmática de Transporte de Serotonina , Fatores de Tempo , Distribuição Tecidual , Tirosina 3-Mono-Oxigenase/genéticaRESUMO
The effect of Gi/o protein-coupled receptors on adenylyl cyclase type 2 (AC2) has been studied in Sf9 insect cells. Stimulation of cells expressing AC2 with the phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) led to a twofold stimulation of cAMP synthesis that could be blocked with the protein kinase C inhibitor GF109203X. Activation of a coexpressed alpha2A-adrenoceptor or muscarinic M4 receptor inhibited the stimulation by TPA almost completely in a pertussis toxin-sensitive manner. Activation of Gs proteins switched the response of the alpha2A-adrenoceptor to potentiation of prestimulated AC2 activity. The potentiation, but not the inhibition, could be blocked by a Gbetagamma scavenger. A novel methodological approach, whereby signalling through endogenous G proteins was ablated, was used to assess specific G protein species in the signal pathway. Expression of Go proteins (alphao1 + beta1gamma2) restored both the inhibition and the potentiation, whereas expression of Gi proteins (alphai1 + beta1gamma2) resulted in a potentiation of both the TPA- and the Gs-stimulated AC2 activity. The data presented supports the view of AC2 as a molecular switch and implicates this isoform as a target for Go protein-linked signalling.
Assuntos
Adenilil Ciclases/metabolismo , Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP/metabolismo , Proteínas Heterotriméricas de Ligação ao GTP/metabolismo , Animais , Ligação Competitiva/efeitos dos fármacos , Ligação Competitiva/fisiologia , Linhagem Celular , Colforsina/farmacologia , AMP Cíclico/metabolismo , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Ativadores de Enzimas/farmacologia , Inibidores Enzimáticos/farmacologia , Subunidades alfa Gs de Proteínas de Ligação ao GTP/metabolismo , Guanosina 5'-O-(3-Tiotrifosfato)/farmacocinética , Humanos , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Toxina Pertussis/farmacologia , Proteína Quinase C/antagonistas & inibidores , Receptores Adrenérgicos alfa 2/metabolismo , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Spodoptera , Acetato de Tetradecanoilforbol/farmacologiaRESUMO
RX 821002 is the 2-methoxy congener of idazoxan. In binding and tissue studies it behaves as a selective antagonist of alpha(2)-adrenoceptors, with at least 5 times greater affinity for these receptors than any other binding site. It does not select between the different types of alpha(2)-receptor. Although this drug probably has no future as a therapeutic agent, it remains a good probe for physiological activity at alpha(2)-adrenoceptors in animal experiments. A particularly useful feature of this compound is its lack of binding at I(1) and I(2) imidazoline receptors. However, it has relatively high affinity for 5-HT(1A) receptors (at which it acts as an antagonist) and a tendency to behave as an inverse agonist at alpha(2A)-adrenoceptors in some cell culture systems. These potential drawbacks may be overcome by careful design of experiments, and the greater selectivity of RX 821002 renders it much superior to yohimbine or idazoxan as a tool for probing physiological actions at alpha(2)-receptors. It can be compared favorably with other selective antagonists such as atipamezole. In physiological studies, RX 821002 augments norepinephrine release in the frontal cortex and increases drinking behavior in rat. In rabbit, intrathecal administration of this drug enhances somatic and autonomic motor outflows, showing that tonic adrenergic descending inhibition of withdrawal reflexes and sympathetic pre-ganglionic neurons is strong in this species. The potentiation of reflexes may be considered a pro-nociceptive action. In the same model, RX 821002 antagonizes the inhibitory effects of the mu opioid fentanyl, indicating that exogenous opioids synergize with endogenously released norepinephrine in the spinal cord. Thus, the careful use of RX 821002 has revealed several aspects of the physiological activity of alpha(2)-adrenoceptors in rabbit spinal cord and rat brain. We recommend that RX 821002 and/or compounds with similar selectivity for alpha(2)-adrenoceptors (atipamezole, MK-912, RS-79948) should be used in preference to yohimbine or idazoxan in all future studies of this type.
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Encéfalo/efeitos dos fármacos , Idazoxano/farmacologia , Receptores Adrenérgicos alfa 2/efeitos dos fármacos , Medula Espinal/efeitos dos fármacos , Agonistas alfa-Adrenérgicos/farmacologia , Antagonistas Adrenérgicos alfa/farmacocinética , Animais , Comportamento Animal/efeitos dos fármacos , Encéfalo/fisiologia , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Receptores de Imidazolinas , Norepinefrina/farmacologia , Medição da Dor , Coelhos , Ratos , Receptores de Droga/metabolismo , Receptores de Serotonina/efeitos dos fármacos , Receptores 5-HT1 de Serotonina , Medula Espinal/fisiologiaRESUMO
The three alpha(2)-adrenergic receptor subtypes have distinct tissue distributions, desensitization properties, and, in some cell types, subtype-specific subcellular localization and trafficking properties. The subtypes also differ in their neuronal physiology. Therefore, we have investigated the localization and targeting of human alpha(2)-adrenoceptors (alpha(2)-AR) in PC12 cells, which were transfected to express the alpha(2)-AR subtypes A, B, and C. Inspection of the receptors by indirect immunofluorescence and confocal microscopy showed that alpha(2A)-AR were mainly targeted to the tips of the neurites, alpha(2B)-AR were evenly distributed in the plasma membrane, and alpha(2C)-AR were mostly located in an intracellular perinuclear compartment. After agonist treatment, alpha(2A)- and alpha(2B)-AR were internalized into partly overlapping populations of intracellular vesicles. Receptor subtype-specific changes in PC12 cell morphology were also discovered: expression of alpha(2A)-AR, but not of alpha(2B)- or alpha(2C)-AR, induced differentiation-like changes in cells not treated with NGF. Also alpha(2B)-AR were targeted to the tips of neurites when they were coexpressed in the same cells with alpha(2A)-AR, indicating that the targeting of receptors to the tips of neurites is a consequence of a change in PC12 cell membrane protein trafficking that the alpha(2A)-subtype induces. The marked agonist-induced internalization of alpha(2A)-AR observed in both nondifferentiated and differentiated PC12 cells contrasts with earlier results from non-neuronal cells and points out the importance of the cellular environment for receptor endocytosis and trafficking. The targeting of alpha(2A)-AR to nerve terminals in PC12 cells is in line with the putative physiological role of this receptor subtype as a presynaptic autoreceptor.
Assuntos
Membrana Celular/fisiologia , Neuritos/fisiologia , Receptores Adrenérgicos alfa 2/fisiologia , Antagonistas Adrenérgicos alfa/farmacocinética , Animais , Diferenciação Celular , Membrana Celular/ultraestrutura , DNA Complementar , Técnica Indireta de Fluorescência para Anticorpo , Humanos , Idazoxano/análogos & derivados , Idazoxano/farmacocinética , Microscopia Confocal , Neuritos/ultraestrutura , Células PC12 , Ratos , Receptores Adrenérgicos alfa 2/análise , Receptores Adrenérgicos alfa 2/genética , Proteínas Recombinantes/análise , Proteínas Recombinantes/biossíntese , TransfecçãoRESUMO
PURPOSE: To characterize the subtypes of alpha1- and alpha2-adrenoceptors in the human corpus cavernosum from patients undergoing sex change surgery. MATERIALS AND METHODS: Saturation and competition radioligand binding studies were performed for characterization at the protein level. Alpha1-adrenoceptors were labeled with [3H]prazosin and [3H]tamsulosin, while alpha2-adrenoceptors were labeled with [3H]RX 821002. Alpha1-adrenoceptor subtype mRNA was additionally determined by reverse-transcriptase polymerase chain reaction and RNase protection assays. RESULTS: Human corpus cavernosum expressed approximately 32 and approximately 22 fmol./mg. protein alpha1- and alpha2-adrenoceptors, respectively. Competition studies with the alpha1A-selective antagonists 5-methylurapidil and (+)-niguldipine and the alpha1D-selective BMY 7378 revealed a mixed alpha1A/alpha1B-adrenoceptor population with no evidence for alpha1D-adrenoceptor protein. In contrast alpha1D-adrenoceptors were readily detected at the mRNA level. Competition binding studies with the alpha2A-selective oxymetazoline and the alpha2B-selective prazosin and ARC 239 revealed a homogeneous population of alpha2A-adrenoceptors. CONCLUSIONS: We conclude that human corpus cavernosum expresses predominantly alpha1A-, alpha1B- and alpha2A-adrenoceptor protein; additionally the alpha1D-adrenoceptor is present at the mRNA level.